
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed his views on toxicities and costs associated with CAR-T, and when and how the field should address them.
A recent patient death following treatment with the gene therapy raised concerns for the European Medicines Agency.
The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed his view on how the cell therapy field should proceed with regard to innovation.
In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.
The designations apply to lupus, myositis, and scleroderma indications.
The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications.
David-Alexandre Gros, MD, the chief executive officer of Eledon Pharmaceuticals, also discussed other future plans for the company.
Review top news and interview highlights from the week ending April 4, 2025.
The move was made in relation to the previously-announced death of a US teenager who received the therapy.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The chief executive officer of Eledon Pharmaceuticals also discussed other future plans for the company.
Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.
The product is marketed under the name Qfitlia.
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner, discussed the necessity of policy and funding efforts for neuromuscular disorders, the stress on the clinical care system, and the need to acknowledge healthcare inequities.
Natalie Goedeker, CPNP, the codirector of pediatric neuromuscular clinical research at Washington University in St. Louis, discussed the session she chaired at MDA’s 2025 conference.
David-Alexandre Gros, MD, the chief executive officer of Eledon Pharmaceuticals, discussed the company’s investigational monoclonal antibody and its use along with EGenesis porcine kidney transplant product.
Review top news and interview highlights from the week ending March 28, 2025.
The codirector of pediatric neuromuscular clinical research at Washington University in St. Louis discussed the session she chaired at MDA’s 2025 conference.
The chief executive officer of Eledon Pharmaceuticals discussed the company’s investigational monoclonal antibody and its use along with EGenesis porcine kidney transplant product.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
According to Secretome, the first-in-human, open-label trial is the first trial to assess an allogeneic stem cell therapy product for HFpEF.
In observance of National Colorectal Cancer Awareness Month, held annually in March, we took a look back at news in cell therapy for colorectal cancer indications.
Michael Flanagan, PhD, the chief scientific officer at Avidity, discussed the function and mechanism of the investigational antisense treatment, which is in development for DMD amenable to exon 44 skipping.
The product is marketed under the name Amvuttra.
One of the patients, who was aged 3 years at the time of treatment, achieved 122.3% microdystrophin expression compared to control.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
OAV101 IT is a version of Zolgensma that is delivered directly to the spine.
Acute liver injury is known to be a possible adverse event associated with AAV vector-based gene therapies such as Elevidys.